MeSH term
Frequency | Condition_Probility | Female | 5 | 0.0 |
Humans | 49 | 0.0 |
Immunoblotting | 4 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Male | 3 | 0.0 |
Nuclear Pore Complex Proteins/*metabolism | 5 | 38.0 |
Research Support, Non-U.S. Gov't | 38 | 0.0 |
Animals | 34 | 0.0 |
Blotting, Western | 4 | 0.0 |
COS Cells | 4 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Hela Cells | 34 | 0.0 |
Microscopy, Fluorescence | 10 | 0.0 |
Nuclear Pore Complex Proteins/*chemistry/metabolism | 2 | 66.0 |
Protein Binding | 12 | 0.0 |
Protein Structure, Tertiary | 7 | 0.0 |
Recombinant Fusion Proteins/metabolism | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 24 | 0.0 |
Xenopus | 12 | 2.0 |
Active Transport, Cell Nucleus | 6 | 2.0 |
Cell Line | 10 | 0.0 |
Green Fluorescent Proteins | 5 | 0.0 |
Interphase | 2 | 1.0 |
Luminescent Proteins/metabolism | 4 | 1.0 |
Nuclear Envelope/metabolism/ultrastructure | 2 | 25.0 |
Nuclear Proteins/*metabolism | 7 | 1.0 |
Rats | 11 | 0.0 |
Mice | 5 | 0.0 |
Peptide Fragments | 2 | 2.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Heterogeneous-Nuclear Ribonucleoproteins | 3 | 2.0 |
Karyopherins/metabolism | 3 | 14.0 |
Macromolecular Substances | 3 | 0.0 |
Microscopy, Immunoelectron | 5 | 0.0 |
Nuclear Pore Complex Proteins/*physiology | 2 | 66.0 |
Nuclear Proteins/genetics/*metabolism | 4 | 1.0 |
Oocytes | 3 | 2.0 |
Xenopus laevis | 4 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Cell Nucleus/*metabolism | 11 | 2.0 |
Cloning, Molecular | 5 | 0.0 |
Comparative Study | 5 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Oocytes/metabolism | 3 | 1.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Recombinant Proteins/metabolism | 8 | 0.0 |
Species Specificity | 2 | 0.0 |
Binding Sites | 4 | 0.0 |
*Nucleocytoplasmic Transport Proteins | 4 | 10.0 |
*Receptors, Cytoplasmic and Nuclear | 5 | 5.0 |
Membrane Proteins/metabolism | 6 | 1.0 |
Microscopy, Confocal | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Mitosis | 2 | 0.0 |
*Nuclear Pore Complex Proteins | 22 | 31.0 |
Time Factors | 3 | 0.0 |
Caspases/antagonists & inhibitors/*metabolism | 2 | 3.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Dactinomycin/pharmacology | 4 | 1.0 |
Karyopherins | 7 | 25.0 |
ran GTP-Binding Protein/metabolism | 2 | 10.0 |
Mutagenesis | 3 | 0.0 |
Mutation | 3 | 0.0 |
Escherichia coli | 2 | 0.0 |
Kidney | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Models, Biological | 6 | 0.0 |
Protein Transport | 3 | 0.0 |
Biological Transport | 9 | 0.0 |
Cell Division | 2 | 0.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Gene Targeting | 2 | 0.0 |
Nuclear Pore/*metabolism | 4 | 36.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Gene Products, rev/*metabolism | 2 | 20.0 |
Microinjections | 2 | 0.0 |
Active Transport, Cell Nucleus/*physiology | 3 | 8.0 |
Cell Nucleus/*physiology | 3 | 11.0 |
Cytoplasm/physiology | 3 | 8.0 |
Nuclear Pore/*physiology | 2 | 100.0 |
Transfection | 5 | 0.0 |
Zinc Fingers | 3 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Ovum | 2 | 12.0 |
Precipitin Tests | 3 | 0.0 |
Phosphorylation | 2 | 0.0 |
Nuclear Envelope/*metabolism | 4 | 14.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 2 | 1.0 |
Nuclear Envelope/*physiology | 2 | 66.0 |
Nuclear Proteins/*physiology | 2 | 1.0 |
3T3 Cells | 3 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Nuclear Envelope/metabolism | 4 | 12.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Zinc Fingers/genetics | 2 | 1.0 |
ran GTP-Binding Protein | 6 | 13.0 |
Cell Nucleus/metabolism | 4 | 0.0 |
Dimerization | 2 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Cell Nucleolus/metabolism | 2 | 5.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Nuclear Proteins/biosynthesis/*chemistry/*metabolism | 2 | 66.0 |
alpha Karyopherins | 2 | 20.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
beta Karyopherins | 3 | 20.0 |
ran GTP-Binding Protein/*metabolism | 2 | 14.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Base Sequence | 4 | 0.0 |
DNA Primers | 2 | 0.0 |
Point Mutation | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
